Post-COVID-19 Hyperglycemia: A Concern in Selection of Therapeutic Regimens | ||
| Iranian Journal of Medical Sciences | ||
| مقاله 1، دوره 46، شماره 4، مهر 2021، صفحه 235-236 اصل مقاله (166.58 K) | ||
| نوع مقاله: Editorial | ||
| شناسه دیجیتال (DOI): 10.30476/ijms.2021.47666 | ||
| نویسنده | ||
| Manica Negahdaripour* 1، 2 | ||
| 1Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran | ||
| 2Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran | ||
| چکیده | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA betacoronavirus responsible for coronavirus disease 2019 (COVID-19), has already caused nearly four million deaths around the world according to the WHO data. | ||
| کلیدواژهها | ||
| COVID-19؛ Hyperglycemia؛ Therapeutic Regimens | ||
| مراجع | ||
|
| ||
|
آمار تعداد مشاهده مقاله: 4,514 تعداد دریافت فایل اصل مقاله: 2,747 |
||